Is BNTX or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Vaxcyte N/A -32.51% -29.51%

Does the media favor BNTX or PCVX?

In the previous week, Vaxcyte had 2 more articles in the media than BioNTech. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.80 beat Vaxcyte's score of 1.46 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ROIV or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,629.19% -20.54% -19.43% Vaxcyte N/A -32.51% -29.51%

Does the media refer more to ROIV or PCVX?

In the previous week, Roivant Sciences had 5 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Roivant Sciences and 5 mentions for Vaxcyte. Roivant Sciences' average media sentiment score of 1.50 beat Vaxcyte's score of 1.46 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, INSM or PCVX?

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 35.19 -$1.28B -$5.75 N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is INSM or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Vaxcyte's return on equity of -32.51% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Vaxcyte N/A -32.51% -29.51%

Does the media prefer INSM or PCVX?

In the previous week, Insmed had 9 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Insmed and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.46 beat Insmed's score of 1.29 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Vaxcyte N/A -32.51% -29.51%

Does the media favor MRNA or PCVX?

In the previous week, Moderna had 23 more articles in the media than Vaxcyte. MarketBeat recorded 28 mentions for Moderna and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.46 beat Moderna's score of 0.65 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 16 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTRS or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Vaxcyte N/A -32.51% -29.51%

Does the media refer more to VTRS or PCVX?

In the previous week, Vaxcyte had 1 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Vaxcyte and 4 mentions for Viatris. Vaxcyte's average media sentiment score of 1.46 beat Viatris' score of 0.90 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vaxcyte (PCVX) Competitors

$50.67 +1.36 (+2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$51.80 +1.13 (+2.23%)

As of 07:58 PM Eastern

Compare

PCVX vs. BNTX, ROIV, INSM, MRNA, and VTRS

Should you buy Vaxcyte stock or one of its competitors? MarketBeat compares Vaxcyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaxcyte include BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Vaxcyte compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioNTech currently has a consensus target price of $129.56, suggesting a potential upside of 40.49%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 69.73%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Vaxcyte had 2 more articles in the media than BioNTech. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.80 beat Vaxcyte's score of 1.46 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Vaxcyte	N/A	-32.51%	-29.51%

Vaxcyte has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.31	-$1.29B	-$5.88	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

BioNTech beats Vaxcyte on 10 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Roivant Sciences has higher revenue and earnings than Vaxcyte. Roivant Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,716.86	-$299.77M	-$0.60	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Roivant Sciences presently has a consensus price target of $33.59, suggesting a potential upside of 7.66%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 69.73%. Given Vaxcyte's higher probable upside, analysts clearly believe Vaxcyte is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Roivant Sciences had 5 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Roivant Sciences and 5 mentions for Vaxcyte. Roivant Sciences' average media sentiment score of 1.50 beat Vaxcyte's score of 1.46 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Vaxcyte	N/A	-32.51%	-29.51%

Roivant Sciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Summary

Roivant Sciences beats Vaxcyte on 10 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to Insmed?

Insmed (NASDAQ:INSM) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Insmed had 9 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Insmed and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.46 beat Insmed's score of 1.29 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Vaxcyte's return on equity of -32.51% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Vaxcyte	N/A	-32.51%	-29.51%

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.19	-$1.28B	-$5.75	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Insmed currently has a consensus target price of $211.86, suggesting a potential upside of 115.20%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 69.73%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Vaxcyte beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Moderna?

Moderna (NASDAQ:MRNA) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Vaxcyte has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Vaxcyte	N/A	-32.51%	-29.51%

Moderna presently has a consensus price target of $36.60, indicating a potential downside of 40.78%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 69.73%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

75.3% of Moderna shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vaxcyte has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	11.13	-$2.82B	-$8.15	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, Moderna had 23 more articles in the media than Vaxcyte. MarketBeat recorded 28 mentions for Moderna and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.46 beat Moderna's score of 0.65 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	16 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vaxcyte beats Moderna on 10 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to Viatris?

Viatris (NASDAQ:VTRS) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Viatris currently has a consensus target price of $17.50, indicating a potential upside of 11.25%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 69.73%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Vaxcyte had 1 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Vaxcyte and 4 mentions for Viatris. Vaxcyte's average media sentiment score of 1.46 beat Viatris' score of 0.90 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.56B	1.26	-$3.51B	-$0.26	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Vaxcyte has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Vaxcyte	N/A	-32.51%	-29.51%

Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

79.9% of Viatris shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vaxcyte beats Viatris on 11 of the 15 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCVX vs. The Competition

Export

Metric	Vaxcyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.32B	$3.40B	$6.42B	$12.06B
Dividend Yield	N/A	2.26%	2.67%	5.64%
P/E Ratio	-7.36	19.72	24.58	24.08
Price / Sales	N/A	181.62	491.62	87.72
Price / Cash	N/A	125.07	44.13	56.69
Price / Book	2.47	8.18	10.63	6.63
Net Income	-$766.63M	$23.94M	$3.57B	$337.89M
7 Day Performance	11.56%	4.06%	1.42%	1.65%
1 Month Performance	-3.28%	1.69%	2.01%	3.10%
1 Year Performance	50.62%	51.98%	27.77%	29.69%

Vaxcyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCVX Vaxcyte	2.919 of 5 stars	$50.67 +2.8%	$86.00 +69.7%	+43.6%	$7.32B	N/A	N/A	160	Positive News
BNTX BioNTech	4.5752 of 5 stars	$90.80 +0.3%	$129.56 +42.7%	-15.8%	$22.90B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	1.9693 of 5 stars	$30.03 0.0%	$33.59 +11.9%	+174.5%	$21.61B	$8.26M	N/A	860	Positive News
INSM Insmed	3.3709 of 5 stars	$97.46 -0.4%	$212.50 +118.0%	-6.0%	$21.21B	$606.42M	N/A	1,664	Positive News Analyst Forecast
MRNA Moderna	1.3224 of 5 stars	$52.13 +4.4%	$36.60 -29.8%	+113.1%	$19.80B	$1.94B	N/A	4,700	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCVX) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Competitors